Transcranial direct current stimulation, alongside aerobic exercise, may improve fatigue in patients with GPA. A patient with granulomatosis with polyangiitis (GPA)—a form of antineutrophil ...

Fetuses treated with intrauterine transfusions faced lower rates of complications with intrahepatic access compared to other approaches, highlighting a need for standardization. Marked variability ...

Patients with mastocytosis mostly had similar rates of atopy and allergies as the general population, except for certain conditions such as asthma. While patients with mastocytosis (both systemic [SM] ...

ADI-001 therapy demonstrated a strong safety profile with low rates of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Researchers have developed a novel T-cell ...

Dr. Vishnevetsky is heading a groundbreaking clinical trial of the cannabinoid spray nabiximols for treating the symptoms of NMOSD. Larry Luxner, senior correspondent for Rare Disease Advisor, ...

Closeup of cannabis leaves and flowers at the Curio Wellness grow facility in Timonium, Maryland (Photo by Larry Luxner) Massachusetts General Hospital is formalizing federal approvals to test a ...

Which of the statements below about the facts of hemolytic disease of the fetus and newborn (HDFN) are correct? Select one of the options for each question, then submit your answers to see how well ...

Mepolizumab is a new therapeutic that holds potential in improving clinical outcomes in EGPA both safety and effectively. Researchers found that mepolizumab is useful in aiding disease control in ...

Avapritinib, a selective KIT mutation-targeted tyrosine kinase inhibitor, has already been approved in the US and Europe for the treatment of adults with indolent SM. A recent analysis of PIONEER data ...

Results showed that patients on efgartigimod had evidence of clinical improvement and a decreased risk of relapse compared to those on placebo. Patients with chronic inflammatory demyelinating ...

The annualized relapse rate was significantly lower in patients treated with biologics compared to patients treated with prednisolone monotherapy and immunosuppressants. Biologics are more efficient ...

Risks and uncertainty around novel gene therapies for rare diseases such as Friedreich ataxia (FA) raise concerns about equity of access and truly informed consent for patients, according to an ...